Nov 30, 2018Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218Novel investigational RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection Subject dosing commenced SAN...